With new rules looming in Europe, contract drugmaker Recipharm intends to invest $45 million (€40 million) over the next three years to improve its drug traceability capabilities for clients. It will invest across its manufacturing network to add new coding and serialization technologies that will enable products to be tagged and traced with identifiable markers that can help thwart counterfeiting. The move comes on the heels of the EU Falsified Medicines Directive, which will require new measures in drug manufacturing starting in 2019. More from FierceCRO